Literature DB >> 24488069

Rebuttal from Zoltan Papp, Attila Borbely and Walter J. Paulus.

Zoltán Papp1, Attila Borbély, Walter J Paulus.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24488069      PMCID： PMC3930425          DOI： 10.1113/jphysiol.2013.268904

Source DB:  PubMed          Journal:  J Physiol        ISSN： 0022-3751            Impact factor:   5.182


× No keyword cloud information.
  10 in total

1.  Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina.

Authors:  Vincent M Figueredo; Gregg S Pressman; Abel Romero-Corral; Elmer Murdock; Pat Holderbach; D Lynn Morris
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-10-05       Impact factor: 2.457

2.  CrossTalk proposal: The late sodium current is an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction).

Authors:  Marc Pourrier; Sarah Williams; Donald McAfee; Luiz Belardinelli; David Fedida
Journal:  J Physiol       Date:  2014-02-01       Impact factor: 5.182

3.  Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability.

Authors:  Victor A Maltsev; Norman Silverman; Hani N Sabbah; Albertas I Undrovinas
Journal:  Eur J Heart Fail       Date:  2006-10-24       Impact factor: 15.534

4.  Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.

Authors:  Raffaele Coppini; Cecilia Ferrantini; Lina Yao; Peidong Fan; Martina Del Lungo; Francesca Stillitano; Laura Sartiani; Benedetta Tosi; Silvia Suffredini; Chiara Tesi; Magdi Yacoub; Iacopo Olivotto; Luiz Belardinelli; Corrado Poggesi; Elisabetta Cerbai; Alessandro Mugelli
Journal:  Circulation       Date:  2012-12-27       Impact factor: 29.690

5.  A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.

Authors:  Luiz Belardinelli; Gongxin Liu; Cathy Smith-Maxwell; Wei-Qun Wang; Nesrine El-Bizri; Ryoko Hirakawa; Serge Karpinski; Cindy Hong Li; Lufei Hu; Xiao-Jun Li; William Crumb; Lin Wu; Dmitry Koltun; Jeff Zablocki; Lina Yao; Arvinder K Dhalla; Sridharan Rajamani; John C Shryock
Journal:  J Pharmacol Exp Ther       Date:  2012-09-25       Impact factor: 4.030

6.  Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease.

Authors:  W Hayashida; C van Eyll; M F Rousseau; H Pouleur
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

7.  Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.

Authors:  Selma F Mohammed; Barry A Borlaug; Véronique L Roger; Sultan A Mirzoyev; Richard J Rodeheffer; Julio A Chirinos; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2012-10-17       Impact factor: 8.790

8.  Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.

Authors:  Samuel Sossalla; Stefan Wagner; Eva C L Rasenack; Hanna Ruff; Sarah L Weber; Friedrich A Schöndube; Theodor Tirilomis; Gero Tenderich; Gerd Hasenfuss; Luiz Belardinelli; Lars S Maier
Journal:  J Mol Cell Cardiol       Date:  2008-03-14       Impact factor: 5.000

9.  Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.

Authors:  Hani N Sabbah; Margaret P Chandler; Takayuki Mishima; George Suzuki; Pervaiz Chaudhry; Omar Nass; Brandon J Biesiadecki; Brent Blackburn; Andrew Wolff; William C Stanley
Journal:  J Card Fail       Date:  2002-12       Impact factor: 5.712

10.  Resveratrol attenuates the Na(+)-dependent intracellular Ca(2+) overload by inhibiting H(2)O(2)-induced increase in late sodium current in ventricular myocytes.

Authors:  Chunping Qian; Jihua Ma; Peihua Zhang; Antao Luo; Chao Wang; Zhiqiang Ren; Linghao Kong; Shuo Zhang; Xiaojing Wang; Ying Wu
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.